News for IMV Stock

IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process IMV Receives NASDAQ Delisting Notice Horizon Technology Finance Announces First Quarter 2023 Financial Results IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency IMV Inc. Announces Changes to Its Board of Directors IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023 IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split IMV Shareholders Approve Reverse Stock Split at 88% IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities IMV Inc. Announces Third Quarter 2022 Financial and Operational Results IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022 IMV Provides an Update on The VITALIZE Trial IMV Inc. Announces Strategic Reorganization IMV Inc. to Present at Two Investor Conferences in September IMV Inc. Announces Second Quarter 2022 Financial and Operational Results IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022 IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency IMV Announces Annual and Special Meeting of Shareholders Voting Results IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility IMV Inc. to Present at the H.C. Wainwright Global Investment Conference IMV Inc. Announces First Quarter 2022 Financial and Operational Results IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022 IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting IMV Inc. Names Michael P. Bailey Chairman of The Board IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting IMV Inc. to Present at Two Upcoming Investor Conferences IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022 IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022 IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL IMV Inc. to Present at Two Upcoming Investor Events IMV Appoints Andrew Hall as Chief Executive Officer IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference IMV Inc. Announces Chief Financial Officer to Retire Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021 Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics IMV Inc. to Present at Three Investor Conferences in September IMV Inc. Announces Second Quarter 2021 Financial and Operational Results IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer IMV Announces CEO Transition IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021 IMV to Participate in the BTIG Virtual Biotechnology Conference IMV Inc. Closes Previously Announced Public Offering IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Units IMV Announces Annual and Special Meeting of Shareholders Voting Results IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor IMV Inc. to Present at Two Upcoming Investor Conferences IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline IMV Appoints Dr. Michael Kalos to Board of Directors IMV’s Lead Immunotherapy to be Investigated in Breast Cancer IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference IMV Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck Following Feedback from FDA IMV Appoints Kyle Kuvalanka to Board of Directors IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results and Host Conference Call and Webcast on March 17, 2021 IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference IMV to Participate in Two Upcoming Investor Events IMV Reports Update on COVID-19 Vaccine Program